AMT Nominates Three Executives to Supervisory Board
Amsterdam Molecular Therapeutics (AMT) has nominated three international pharmaceutical executives to join the Company’s Supervisory Board of Directors: Joseph M. Feczko, Steven H. Holtzman, and François Meyer.
The Company has issued a notice for an Extraordinary General Meeting of Shareholders on September 20, for the election of the nominees. In connection with these proposed appointments, George Morstyn will step down from the Board.
In addition, the company will expand its management team. Dr. Claudia Meyer will join the Company as Director Regulatory Affairs, and Dr. Gerald Haase as a senior clinical consultant.
More information: www.amtbiopharma.com
